BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12973749)

  • 21. [Treatment with NMDA antagonist controls neuron death. Even in severe dementia it is not too late].
    MMW Fortschr Med; 2003 Jan; 145(1-2):56. PubMed ID: 12638448
    [No Abstract]   [Full Text] [Related]  

  • 22. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
    Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
    Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis.
    Gauthier S; Loft H; Cummings J
    Int J Geriatr Psychiatry; 2008 May; 23(5):537-45. PubMed ID: 18058838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Memantine. Merz.
    Kilpatrick GJ; Tilbrook GS
    Curr Opin Investig Drugs; 2002 May; 3(5):798-806. PubMed ID: 12090556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Memantine hydrochloride in the treatment of dementia subtypes.
    Peng D; Yuan X; Zhu R
    J Clin Neurosci; 2013 Nov; 20(11):1482-5. PubMed ID: 24035650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
    Pomara N; Ott BR; Peskind E; Resnick EM
    Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Memantine in the treatment of dementia.
    Maggiore C; Locatelli L; Grandi FC; Pizzolato G;
    Neuroepidemiology; 2007; 28(2):118-9. PubMed ID: 17409774
    [No Abstract]   [Full Text] [Related]  

  • 29. Factors affecting usage patterns of memantine in Alzheimer disease.
    Lerner AJ; McClendon MJ; Sami SA; Ogrocki PK; Adams KB; Smyth KA
    Alzheimer Dis Assoc Disord; 2008; 22(2):137-43. PubMed ID: 18525285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stroke, Alzheimer's patients may benefit from AIDS dementia drug.
    Dent Today; 1997 Feb; 16(2):29. PubMed ID: 9560599
    [No Abstract]   [Full Text] [Related]  

  • 31. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.
    Jönsson L
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):77-86. PubMed ID: 16129384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The chemical biology of clinically tolerated NMDA receptor antagonists.
    Chen HS; Lipton SA
    J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease.
    Grossberg GT; Pejović V; Miller ML; Graham SM
    Dement Geriatr Cogn Disord; 2009; 27(2):164-72. PubMed ID: 19194105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of memantine in community-based Alzheimer's disease patients: An adaptation in Spain.
    Antonanzas F; Rive B; Badenas JM; Gomez-Lus S; Guilhaume C
    Eur J Health Econ; 2006 Jun; 7(2):137-44. PubMed ID: 16670912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis.
    Maidment ID; Fox CG; Boustani M; Rodriguez J; Brown RC; Katona CL
    Ann Pharmacother; 2008 Jan; 42(1):32-8. PubMed ID: 18056833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Behavioral effects of current Alzheimer's disease treatments: a descriptive review.
    Cummings JL; Mackell J; Kaufer D
    Alzheimers Dement; 2008 Jan; 4(1):49-60. PubMed ID: 18631950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 6-month, open-label study of memantine in patients with frontotemporal dementia.
    Diehl-Schmid J; Förstl H; Perneczky R; Pohl C; Kurz A
    Int J Geriatr Psychiatry; 2008 Jul; 23(7):754-9. PubMed ID: 18213609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
    Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
    Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Memantine: new preparation. Poor evaluation and uncertain benefit in Alzheimer's disease.
    Prescrire Int; 2003 Dec; 12(68):203-5. PubMed ID: 14986682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.